Results 91 to 100 of about 381,559 (266)

The Case of a 40‐Year‐Old Man With New‐Onset Status Epilepticus in the Setting of HIV Infection

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT A 40‐year‐old man from Andhra Pradesh in India, while on regular antiretroviral treatment (ART) for long‐standing HIV infection presented with a 1‐day history of new‐onset status epilepticus. CT and MRI brain showed multifocal cerebral ring lesions, some of which demonstrated characteristic ‘hole‐with‐a‐dot’ sign.
Vadde Akhil, Ramachandiran Nandhagopal
wiley   +1 more source

Rheumatologic Manifestations of Patients With Type B Insulin Resistance

Arthritis Care &Research, EarlyView.
Objective The objectives of this study were to identify laboratory and clinical features associated with type B insulin resistance (TBIR), a rare condition caused by autoantibodies that inhibit the insulin receptor, most frequently occurring in the setting of systemic lupus erythematosus (SLE), and to increase awareness of this rare, life‐threatening ...
S. Amara Ogbonnaya, Sandra G. Williams, Raphael A. Kirou, Marissa Lightbourne, Rebecca J. Brown   +4 more
wiley   +1 more source

The Development and Pilot Clinical Study of CD147 Targeted Antagonistic Peptide Probe for Tumor Imaging

Advanced Science, EarlyView.
This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma, Rui Guo, Dongfeng Niu, Yufei Song, Zhenyao Zhang, Xiangxi Meng, Lili Mao, Haifeng Huang, Hua Zhu, Zhi Yang, Teli Liu   +10 more
wiley   +1 more source

ABHD17C‐Mediated S‐Depalmitoylation of BCL6B Enhances CD24 Transcription to Resist Macrophage Phagocytosis in Pancreatic Cancer

Advanced Science, EarlyView.
ABHD17C‐mediated depalmitoylation of BCL6B at Cys442 blocks its nuclear import and triggers ubiquitin‐dependent degradation, attenuating transcriptional repression of the anti‐phagocytic signal CD24. This mechanism enables pancreatic cancer cells to evade macrophage phagocytosis and fosters an immunosuppressive microenvironment.
Yalu Zhang, Di Cui, Fanzheng Meng, Xu Zhu, Liang Zhu, Liang Wu, Haifeng Hu, Jizhou Wang, Hanhui Yao, Lianxin Liu   +9 more
wiley   +1 more source

Zanubrutinib enhances CD19 CAR T killing of B-cell lymphoma by inhibiting BTK phosphorylation, regulating PI3K/AKT/mTOR pathway, and promoting autophagy

Blood Science
Anti-CD19 chimeric antigen receptor T cells (CAR T) still have many limitations, including insufficient clinical efficacy. Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor with higher drug potency, and it is not clear whether it
Hao Yao, Ling Qiu, Shi-Hui Ren, Dan Chen, Meng-Jiao Li, Bai-Tao Dou, Nan Zhang, Xiao Wang, Yi Su, Alex H. Chang, Fang-Yi Fan   +10 more
doaj   +1 more source

SSR4 sustains Tertiary Lymphoid Structures by Regulation Quality Control of N‐linked Glycosylation During B‐cell Differentiation Into Plasmacyte in Colorectal Cancer

Advanced Science, EarlyView.
SSR4, a TRAP component induced in B cells, governs BAFFR N‐glycosylation via DDOST to sustain NF‐κB signaling, B‐cell differentiation, and TLS maturation. Its loss impairs anti‐tumor immunity, while overexpression improves antibody glycosylation and ADCC, revealing a critical regulator for cancer immunotherapy.
Wei Zhao, Youcai Zhao, Haiyang Li, Bowen Yang, Siyan Lu, Xueting Fu, Caixia Zhang, Yirong Chen, Xiaofeng Bian, Xinghua Ma, Xiaobing Yang, Bin Wang, Yuan Fang, Lulu Yang, Yelin Zhao, Shuli Zhao   +15 more
wiley   +1 more source

CEBPG‐Mediated Palmitic Acid Adaptation of Cancer‐Associated Fibroblasts Drives Metastasis of Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
This study reveals a metabolic signaling axis in the OSCC microenvironment where palmitic acid (PA) drives the activation of CAFs. PA uptake triggers CEBPG‐dependent epigenetic remodeling to upregulate ERN1 and TMBIM6, thereby mitigating ER stress. This adaptive program sustains CAF survival and the pro‐metastatic phenotype, establishing this pathway ...
Yiling Duan, Yitong Li, Yufei Wu, Xiao Yang, Rui Li, Hui Zhao, Zhengjun Shang   +6 more
wiley   +1 more source

The toxicity of chimeric antigen receptor T-cell immunotherapy in B-cell lymphoma: a Meta-analysis

Zhongguo aizheng zazhi, 2019
Background and purpose: For patients with relapsed or refractory B-cell lymphoma, conventional therapy is not effective. Researching new treatment technology to improve prognosis is imminent.
勋, 张锡友, 峰, 李丹丹, 董倩倩, 宋清坤, 钟晓松, 李文斌   +7 more
doaj  

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

Frontiers in Oncology
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell ...
Bei Hu, Victoria Korsos, M. Lia Palomba, M. Lia Palomba   +3 more
doaj   +1 more source

Allosteric Inhibition of Polycomb Repressive Complex 2 by an EZH2‐Selective Small Molecule Inhibitor

Advanced Science, EarlyView.
The study characterizes C36, a highly selective EZH2/PRC2 inhibitor that acts via a novel allosteric mechanism. Unlike previous inhibitors, C36 inhibits EZH2/PRC2 by disrupting the allosteric communication between EZH2 and EED in a SAM‐noncompetitive manner.
Ting Cao, Dongdong Liu, Haishan Gao, Chenyang Qin, Wen Zhang, Ziyun Lu, Dongxia Tan, Yuxiu Qu, Yusong Liu, Zhiran Zou, Hongtao Yu, Wei Qi   +11 more
wiley   +1 more source